Background: This study investigated the effectiveness and safety of exercise training (ET) as an adjunctive therapy to montelukast for children with mild asthma (MA).
Introduction
Asthma is one of the most common disorders of respiratory system diseases. [1] [2] [3] [4] It has been estimated that this disorder affects 9% to 20% children and 1% to 3% adults in the United State. [5] [6] In China, the prevalence of asthma is estimated to be about 5%. [7] [8] Additionally, the number of patients diagnosed with asthma is increasing around the world, especially among the children population. [9] [10] [11] [12] [13] [14] [15] [16] Thus, it is very important to treat and to prevent this disorder.
Current managements for asthma mainly use medication, such as glucocorticoids, antihistamine drugs, b2 agonists, and leukotriene receptor antagonists. [17] [18] [19] [20] However, they often have limited efficacy. [21] In addition, those medications often accompanied a variety of adverse events, especially for children with asthma. [22] [23] [24] Thus, more management options with fewer adverse events are urgently needed to treat and to prevent children with asthma. Alternative therapy is one of most important candidates to treat such condition, such as exercise training (ET). However, limited data is available to support ET for the management of asthma in children. [25] In this study, we tested the hypothesis that the effectiveness and safety of ET as an adjunctive therapy to montelukast would be better than the montelukast alone for the treatment of children with mild asthma (MA) ages 4 to 12 years old.
Methods

Ethical approval
This study was approved by the Medical Ethical Committee of Yan'an People's Hospital.
Sample size
The sample size of this study was 60 participants, 30 children in each group with 12% difference of FEV 1 between 2 groups and a=0.05, b=0.1, according to the previous alternative study. [26] The desired sample size for this study is set to 72 subjects, 36 patients each group with assumed dropout rates of 20%.
Design
This study was designed as a 2 arms randomized controlled trial (RCT). It was conducted from January 2017 to June 2018 at Yan'an People's Hospital. Totally, 72 children with MA were recruited in this study. After screen, they were randomly allocated into a treatment group (n = 36, received ET plus montelukast) and a control group (n = 36, received montelukast alone). The lung function, clinical symptoms, and quality of life (QoL) were measured to assess its efficacy. All endpoints were measured at baseline, at the end of 6-week treatment, and 2-week follow-up after the treatment.
Randomization, allocation, and blinding
A total of 72 children with MA were equally and randomly allocated to the treatment group or the control group at a ratio of 1:1 by using a block randomization procedure. The random number was performed by using IBM SPSS Statistics 17.0 (IBM Corp., Armonk, NY). The randomization information was kept in opaque sealed envelopes. The outcome assessors and data analysts were masked to the study allocation.
2.5. Inclusion and exclusion criteria 2.5.1. Inclusion criteria. The both boys and girls were considered to be included if they were ages between 4 and 12 years old. All of them were diagnosed confirm as MA (symptoms occurred less than once weekly). In addition, the legal guardians of each child signed the informed written consent before the study.
Exclusion criteria.
The children with MA were excluded if they had a history of exercise induced asthma; received any kinds of medications that help to relive MA 1-month before the study or during the study period; other severe diseases such as cancers, heart failure, and respiratory infections.
Intervention
All children in both groups received chewable montelukast (4 mg daily) tablet in the evening at bedtime, once daily, for a total of 6 weeks. Additionally, children in the treatment group also received ET program by a certified 5-year experienced training instructor. It included 40 min long aerobic circuit training class. Each child received ET 3 times weekly for a total of 6 weeks.
Endpoint assessments
The primary endpoint of lung function was measured by forced expiratory volume in 1 second (FEV 1 ) [27] and ratio between FEV 1 and forced vital capacity (FEV 1 /FVC). [28] The secondary endpoint of clinical symptoms was assessed by clinical assessment score, and quality of life (QoL) was evaluated with Paediatric Allergic Disease Quality of Life Questionnaire (PADQLQ) scores. [29] The PADQLQ scale consists 26 items, the scores of each item range from 0, not bothered, to 6, extremely bothered. The higher score indicates the worse QoL. Moreover, any adverse events were also recorded during the study period.
The spirometry was utilized to measure FEV 1 and FEV 1 /FVC by using PiKo-1 (ATS and EU electronic peak flow monitor, Ferraris Respiratory Europe Ltd., Westford SG13 7NW, UK) software. It was conducted by an experienced physician who had attended the training class before the study. All outcomes were measured at baseline, at the end of 6-week treatment, and 2-week follow-up after the treatment.
Statistical analysis
All characteristic data and endpoint values were analyzed by using IBM SPSS Statistics 17.0 (IBM Corp., Armonk, NY) by using intent-to-treat (ITT) analysis. The categorical data was applied by using Chi-squared test, while the continuous data was operated by using t test or Mann-Whitney U test to analyze the differences between 2 groups. The statistical significance was defined as P < .05 (2-tailed).
Results
A total of 105 eligible children with MA entered the study (Fig. 1) . Of them, 27 did not meet the criteria, and were excluded. In addition, 6 of them rejected to participate in this study. Thus, a total of 72 children with MA were included in this study, and were equally allocated into the treatment group and the control group. Although 4 and 7 patients respectively withdraw at the end of 6-week treatment and 2-week follow-up respectively, all of them entered the final analysis by using ITT analysis (Fig. 1) .
The comparisons of patient characteristics between 2 groups are summarized in Table 1 . The comparisons of 2 groups did not differ significantly in all characteristics and clinical variables in this study, such as age, sex, race, asthma history, disease duration, and endpoints at baseline.
At the end of 6-week treatment, patients who received ET plus montelukast exerted better effectiveness in clinical symptoms relief (P < .01, Table 2 ) and QoL improvement (P < .01, Table 2 ), although the lung function did not show promising effective results with FEV 1 (P = .80, Table 3 ) and FEV 1 /FVC (P = .44, Table 3 ), compared with patients who received montelukast alone. This trend kept steady throughout the period of 2-week follow-up with clinical symptoms relief (P < .01, Table 2 ), QoL improvement (P < .01, Table 2 ), and lung function, as assessed with FEV 1 (P = .70, Table 3 ) and FEV 1 /FVC (P = .41, Table 3 ) between 2 groups.
All adverse events recorded in this study were mild (Table 4) . No adverse events related to the ET occurred in the treatment group. No serious adverse event, as well as the treatment related death was recorded during the study period in either group. No significant differences regarding all adverse events were detected between 2 groups (Table 4 ).
Discussion
Although several previous studies have reported that montelukast monotherapy has been utilized to treat children with asthma, [30] [31] [32] [33] its efficacy is still limited and also has a variety of adverse events. Thus, in order to improve its efficacy, alternative add-on therapy should be added to manage such disorder.
A previous published study has addressed the effect of ET plus montelukast for the treatment of children with EA. [25] Its results demonstrated that ET could decrease bronchial responsiveness to methacholine. It suggested that the combination of ET and montelukast provided beneficial action in children with MA. However, that study focused only on Italy children, and also had a relative small sample size, and did not evaluate the clinical symptoms and QoL in children with MA.
The results of the present study are partly consistent with the previous study.
[ 25] In the present study, the findings showed that ET as an adjunctive therapy to the montelukast can significantly relieve the clinical symptoms and also can improve the QoL in patients with EA, except no significant differences in lung function were found between 2 groups. It may be because the duration of this study was not long enough to present the positive results for this therapy with only 6 weeks treatment.
The results of this study indicated that ET as an adjunctive therapy to the montelukast may still benefit for children with MA. The present study has several drawbacks. First, the sample size was still quite small in this study, which may impact its results. Second, the duration of this study may be insufficient to show the better promising efficacy for ET plus montelukast. Thus, future studies should extend their treatment duration to further warrant the results of this study. Third, although this study is a RCT study, the investigators and patients were not blinded, except the outcome assessors and data analyst, which may impact the patient selection in this study. The further studies should avoid these drawbacks.
Conclusion
The findings of this study showed that ET as an adjunctive therapy to the montelukast may benefit for children with EA after 6-week treatment. More studies with longer treatment duration are still needed to warrant the results of the present study. Table 2 Comparison of secondary endpoints at the end of 6-week treatment and 2-week follow-up. Data are present as mean ± standard difference; PADQLQ = Paediatric Allergic Disease Quality of Life Questionnaire scores. Table 4 Comparison of adverse events between 2 groups.
Safety
Treatment group (n = 36) Control group (n = 36) P Data are present as mean ± standard deviation.
Table 3
Comparison of primary endpoint at the end of 6-week treatment and 2-week follow-up. 
